Dr. Sarah Elizabeth Hoffe, MD

Dr. Hoffe practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Hoffe's NPI, 1114995917, was assigned on March 9, 2006. Dr. Hoffe graduated from The Robert Larner, M.D. College of Medicine in 1993. Dr. Hoffe holds Florida license ME76408.

Dr. Hoffe's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Hoffe's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Hoffe to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hoffe practices, 2 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Hoffe's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Hoffe is board certified in radiation oncology by the American Board of Radiology. Dr. Hoffe is licensed in Florida.

Dmand AI lists anal cancer radiation, bone cancer radiation, cancer radiation-upper GI, colorectal cancer radiation, lung cancer radiation and pancreatic cancer radiation among the conditions Dr. Hoffe treats.

CMS data shows 1,417 Medicare services from Dr. Hoffe across 14 procedure codes in 2024, for 261 Medicare patients. Medicare paid $96,791 for them.

CMS counts 261 Medicare patients who saw Dr. Hoffe in 2024. The largest group is 65 to 74, with 136 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 4% are also on Medicaid. Their average risk score is 2.32, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hoffe's median patient age at 68, with 45% women.

In 2024, Dr. Hoffe wrote 57 Medicare Part D claims for 32 patients. 82% of them were for generic drugs. CMS names the drug for 30 of them, across 2 drugs with 11 or more claims each, at $306 in total drug cost. In 2022, CMS named 39 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Hoffe for performance year 2024, reported as part of a group. Dr. Hoffe accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hoffe as offering telehealth.

Dmand AI links 192 papers to Dr. Hoffe, published from 2007 to 2025. 2024 was the busiest year, with 13. The most frequent topics are Adenocarcinoma, Esophageal Neoplasms and Pancreatic Neoplasms. Dr. Hoffe has published most often in Cancer Control. Dr. Hoffe's most frequent co-authors are Jessica M. Frakes, Ravi Shridhar, MD, PhD and Kenneth L. Meredith, MD.

Dmand AI links Dr. Hoffe to 1 clinical trial. Conditions studied include Pancreatic Neoplasms and Pancreatic Diseases.

CMS Open Payments shows 23 general payments to Dr. Hoffe from 10 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 72% of the total. Varian Medical Systems, Inc. paid the most, $5,936.

Dmand AI lists 1 award for Dr. Hoffe, most recently Physician of the Year in 2009.

Dr. Hoffe graduated from The Robert Larner, M.D. College of Medicine in 1993.

Dr. Hoffe is in network with 6 carriers, including Excellus BlueCross BlueShield, United Healthcare and Blue Cross Blue Shield of Michigan. POS plans come from the most carriers, 4. Check the plan with the practice before a visit.